CEO Dr. Hanadie Yousef discusses how the success of GLP-1/GIP receptor agonists is reshaping the treatment of chronic metabolic diseases and driving the next wave of therapeutics targeting the biology of aging at BIO 2025 in Boston
CEO Dr. Hanadie Yousef joins a panel of industry leaders at BIO 2025 to explore how emerging therapeutic categories are reshaping dealmaking strategies, investment trends, and positioning in today’s evolving biotech landscape
Juvena Therapeutics Announces Initiation of First-in-Human Clinical Trial of JUV-161
Juvena Kicks Off First Human Trial of Muscle Regeneration Therapy
Director of Translational Biology and Pharmacology, Priya Handa, PhD, and Senior Director of Discovery and Platform, Thach Mai, showcased our research at the 23rd Biopharma Drug Discovery Nexus Conference in San Francisco
CEO Dr. Hanadie Yousef shares insights on a panel, “Entrepreneurial Excellence in BioPharma: Lessons from the Frontlines,” at SynBioBeta – The Global Synthetic Biology Conference in San Jose
CEO Dr. Hanadie Yousef shares an Industry Update on JUV-161 and our plans to initiate Phase 1 studies this year at the 2025 International MDF Conference in Indianapolis
Pharmaceutical Executive Video Interview: Hanadie Yousef, PhD, Co-Founder and CEO Juvena Therapeutics, Inc. (Link to 5 video clips)
Watch all 5 clips now:
Expanding Disease Indications JUV161
Obesity Muscle Targeting Program
